Automated Insulin Delivery Systems for the Treatment of Elderly People With Type 1 Diabetes: A Case Series and Short Review

The treatment of type 1 diabetes in elderly patients poses several clinical dilemmas, including multiple comorbidities, established complications, impaired cognitive function, frailty, and the increased risk of severe hypoglycemia, which may lead to the pursuit of less stringent glycemic goals ( 1, 2 ). Additionally, technological advances such as continuous glucose monitoring (CGM) systems, sensor-augmented pump (SAP) therapy, and, more recently, hybrid closed-loop automated insulin delivery (AID) systems have changed the landscape of modern type 1 diabetes treatment ( 3 ). However, data on the efficacy and safety of AID in older adults (>70 years of age) with type 1 diabetes are extremely limited.